Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
QNQuoin Pharmaceuticals, Ltd. logo

Quoin Pharmaceuticals, Ltd. (QNRX)

NASDAQ Capital Market · Currency in USD
$3.96 ▼ -0.06 (-1.49%)
As of Oct 26, 1:25 PM ET. Market open.

Summary

Previous Close
$4.02
Open
$3.96
Day's Range
$3.96 – $4.25
52 Week Range
$3.25 – $23.50
Volume
1,142
Avg. Volume
542,629
Market Cap
$7.95M
Beta (5Y Monthly)
1.75
PE Ratio (TTM)
--
EPS (TTM)
-$9.34
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.00

Profile: Quoin Pharmaceuticals, Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4
CEO
Michael Myers

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.52
DateEst.Actual
Aug 14, 2026-$1.83-$1.90Miss
May 7, 2026-$1.80-$1.77Beat
Mar 26, 2026-$6.42-$14.80Miss
Nov 6, 2025-$6.36-$6.71Miss
Aug 7, 2025-$6.83-$6.28Beat
May 13, 2025-$3.85-$6.50Miss

Analyst view

Consensus price target
$17.00 ▲ +329.3%
Range $14.00 – $20.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on QNRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.